HRP20221139T1 - Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) - Google Patents
Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) Download PDFInfo
- Publication number
- HRP20221139T1 HRP20221139T1 HRP20221139TT HRP20221139T HRP20221139T1 HR P20221139 T1 HRP20221139 T1 HR P20221139T1 HR P20221139T T HRP20221139T T HR P20221139TT HR P20221139 T HRP20221139 T HR P20221139T HR P20221139 T1 HRP20221139 T1 HR P20221139T1
- Authority
- HR
- Croatia
- Prior art keywords
- pen
- antibody
- amino acid
- seq
- injector
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 229940100601 interleukin-6 Drugs 0.000 title 1
- 229940090048 pen injector Drugs 0.000 claims 17
- 229940090047 auto-injector Drugs 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 8
- 102000052623 human IL6R Human genes 0.000 claims 8
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/065—Rigid ampoules, e.g. glass ampoules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Olovka ili autoinjektor koji sadrže farmaceutsku formulaciju, pri čemu farmaceutska formulacija sadrži:
(i) humano antitijelo koje se specifično vezuje za humani interleukin-6 receptor (hIL-6R), pri čemu antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 18 i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 26;
(ii) histidin u koncentraciji od 10 mM do 25 mM;
(iii) arginin u koncentraciji od 25 mM do 50 mM;
(iv) saharozu u količini od 5% do 10% mas/v; i
(v) polisorbat 20 u količini od 0,1% do 0,2% mas/v.
2. Olovka ili autoinjektor prema patentnom zahtjevu 1, gdje je antitijelo u koncentraciji od 5 mg/ml do 200 mg/ml.
3. Olovka ili autoinjektor prema patentnom zahtjevu 1 ili 2, pri čemu formulacija ima pH u vrijednosti od 6 ± 1 %.
4. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se najmanje 90% prirodnog oblika antitijela regenerira nakon devet mjeseci skladištenja na 5°C, kako je određeno tekućinskom kromatografijom visoke djelotvornosti s ekskluzijom prema veličini (SE-HPLC).
5. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se najmanje 95% prirodnog oblika antitijela regenerira nakon devet mjeseci skladištenja na 5°C, kako je određeno tekućinskom kromatografijom visoke djelotvornosti s ekskluzijom prema veličini (SE-HPLC).
6. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se najmanje 96% prirodnog oblika antitijela obnavlja poslije devet mjeseci skladištenja na 5°C, kako je određeno tekućinskom kromatografijom visoke djelotvornosti s ekskluzijom prema veličini (SE-HPLC).
7. Olovka ili autoinjektor prema patentnom zahtjevu 1, koji sadrži:
(i) 25 do 200 mg/ml humanog antitijela koje se specifično vezuje za humani interleukin-6 receptor (hIL-6R), pri čemu antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 18 i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 26;
(ii) oko 25 mM histidina;
(iii) oko 5% mas/v saharoze; i
(iv) oko 0,2% mas/v polisorbata 20; i
(v) oko 50 mM arginina, pri čemu “oko” znači ±1 %
8. Olovka ili autoinjektor prema patentnom zahtjevu 1, koji sadrži:
(i) oko 175 mg/mL humanog antitijela koje se specifično vezuje za humani interleukin-6 receptor (hIL-6R), pri čemu antitijelo sadrži varijabilnu regiju lakog i teškog lanca (HCVR / LCVR) para aminokiselinskih sekvenci SEQ ID NO: 18/26 ;
(ii) oko 25 mM histidina;
(iii) oko 5% saharoze;
(iv) oko 0,2% polisorbata 20; i
(v) oko 50 mM arginina, pri čemu "oko" znači ±1%.
9. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu se humano antitijelo koje se specifično vezuje za hIL-6R sastoji od dva teška lanca i dva laka lanca; svaki teški lanac sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 18 i konstantnu regiju teškog lanca, i svaki laki lanac sadrži varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 26 i konstantnu regiju lakog lanca.
10. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu se humano antitijelo koje se specifično vezuje za hIL-6R sastoji od dva teška lanca i dva laka lanca; svaki teški lanac sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 18 i konstantnu regiju teškog lanca, i svaki laki lanac sadrži varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 26 i konstantnu regiju lakog lanca.
11. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 10, pri čemu injektor predstavlja injektor olovku.
12. Injektor olovka prema patentnom zahtjevu 11, pri čemu je injektor višekratni injektor olovka.
13. Injektor olovka prema patentnom zahtjevu 11, pri čemu je injektor jednokratni injektor olovka.
14. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je injektor autoinjektor.
15. Olovka ili autoinjektor prema bilo kojem od patentnih zahtjeva 1 do 14 za upotrebu za supkutano ubrizgavanje farmaceutske formulacije.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29322710P | 2010-01-08 | 2010-01-08 | |
EP20184418.0A EP3756652B1 (en) | 2010-01-08 | 2011-01-07 | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221139T1 true HRP20221139T1 (hr) | 2022-12-09 |
Family
ID=44258720
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221139TT HRP20221139T1 (hr) | 2010-01-08 | 2011-01-07 | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) |
HRP20181821TT HRP20181821T1 (hr) | 2010-01-08 | 2018-10-31 | Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela |
HRP20201428TT HRP20201428T1 (hr) | 2010-01-08 | 2020-09-08 | Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181821TT HRP20181821T1 (hr) | 2010-01-08 | 2018-10-31 | Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela |
HRP20201428TT HRP20201428T1 (hr) | 2010-01-08 | 2020-09-08 | Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela |
Country Status (39)
Country | Link |
---|---|
US (4) | US9173880B2 (hr) |
EP (4) | EP3756652B1 (hr) |
JP (2) | JP5805660B2 (hr) |
KR (1) | KR101787351B1 (hr) |
CN (1) | CN102869346B (hr) |
AR (1) | AR079836A1 (hr) |
AU (1) | AU2011204311B2 (hr) |
BR (1) | BR112012016618A2 (hr) |
CA (1) | CA2790197C (hr) |
CL (1) | CL2012001853A1 (hr) |
CO (1) | CO6592078A2 (hr) |
CR (1) | CR20120393A (hr) |
CY (2) | CY1121420T1 (hr) |
DK (3) | DK2521536T3 (hr) |
DO (1) | DOP2012000193A (hr) |
EC (1) | ECSP12012092A (hr) |
ES (3) | ES2925665T3 (hr) |
GT (1) | GT201200223A (hr) |
HR (3) | HRP20221139T1 (hr) |
HU (3) | HUE051115T2 (hr) |
JO (1) | JO3417B1 (hr) |
LT (3) | LT3756652T (hr) |
MA (1) | MA33993B1 (hr) |
MX (1) | MX2012007794A (hr) |
MY (1) | MY156702A (hr) |
NI (1) | NI201200119A (hr) |
NZ (1) | NZ601114A (hr) |
PE (2) | PE20121687A1 (hr) |
PL (3) | PL2521536T3 (hr) |
PT (3) | PT2521536T (hr) |
RS (3) | RS57903B1 (hr) |
RU (1) | RU2554779C2 (hr) |
SG (1) | SG182283A1 (hr) |
SI (3) | SI2521536T1 (hr) |
TW (2) | TWI533884B (hr) |
UA (1) | UA107211C2 (hr) |
UY (1) | UY33169A (hr) |
WO (1) | WO2011085158A2 (hr) |
ZA (1) | ZA201205035B (hr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
KR101879885B1 (ko) | 2010-09-17 | 2018-07-18 | 박스알타 인코퍼레이티드 | 약산성 내지 중성 ph에서 히스티딘을 갖는 수성 제형을 통한 면역글로불린의 안정화 |
MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
CA2825838C (en) | 2011-01-28 | 2020-10-27 | Sanofi | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
KR20200039028A (ko) * | 2011-10-11 | 2020-04-14 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
DK2790681T4 (da) | 2011-11-18 | 2023-05-01 | Regeneron Pharma | Fremgangsmåde til fremstilling af en farmaceutisk formulering med langvarig frigivelse omfattende polymercoatede proteinmikropartikler ved anvendelse af spraytørring |
NZ627859A (en) * | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
ES2702246T3 (es) * | 2012-03-26 | 2019-02-28 | Sanofi Sa | Formulaciones de agente de unión IgG4 estables |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
BR112015008186A2 (pt) * | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
CA2886987C (en) | 2012-11-08 | 2022-07-12 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
EP3169353B1 (en) | 2014-07-16 | 2019-12-18 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
NZ731090A (en) | 2014-11-07 | 2024-03-22 | F Hoffmann La Roche Ltd | Improved il-6 antibodies |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
EP3419599A4 (en) * | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
CA3016880A1 (en) | 2016-03-07 | 2017-09-14 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
AU2017333367A1 (en) * | 2016-09-27 | 2019-04-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
CA3040342A1 (en) | 2016-10-31 | 2018-05-03 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
AU2017380842A1 (en) * | 2016-12-23 | 2019-07-11 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
CA3083971A1 (en) * | 2017-11-30 | 2019-06-06 | Bio-Thera Solutions, Ltd. | Liquid formulation of humanized antibody for treating il-6 related diseases |
EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
CN111787950A (zh) | 2018-01-05 | 2020-10-16 | 科威迪亚治疗公司 | 用于无免疫抑制地治疗il-6介导的炎症的方法 |
JP7349998B2 (ja) | 2018-01-31 | 2023-09-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法 |
TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
CN111868085A (zh) | 2018-03-19 | 2020-10-30 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
US11319375B2 (en) | 2018-08-29 | 2022-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
EA202190032A1 (ru) | 2018-08-30 | 2021-03-12 | Ридженерон Фармасьютикалз, Инк. | Способы определения характеристик белковых комплексов |
WO2020088346A1 (en) * | 2018-10-31 | 2020-05-07 | Mycenax Biotech Inc. | Aqueous pharmaceutical formulations |
KR20210114926A (ko) | 2019-01-16 | 2021-09-24 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 내에서 유리 티올을 식별하는 방법 |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
TW202106712A (zh) | 2019-04-24 | 2021-02-16 | 美商再生元醫藥公司 | 類風溼性關節炎之診斷及治療方法 |
JP2022532503A (ja) | 2019-05-13 | 2022-07-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
BR112021024445A2 (pt) | 2019-06-04 | 2022-02-15 | Regeneron Pharma | Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide |
WO2020257586A2 (en) | 2019-06-20 | 2020-12-24 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
JP2022548394A (ja) | 2019-09-24 | 2022-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーの使用および再生のためのシステムおよび方法 |
JP2023502500A (ja) | 2019-11-25 | 2023-01-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水性エマルションを使用した持続放出製剤 |
IL303596A (en) | 2020-01-21 | 2023-08-01 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
WO2021163549A1 (en) | 2020-02-14 | 2021-08-19 | Sanofi Biotechnology | Compositions and methods for treating viral infections |
JP2023527059A (ja) | 2020-05-26 | 2023-06-26 | サノフィ・バイオテクノロジー | 関節リウマチを治療するためのインターロイキン6受容体に対する抗体を含む組成物およびその使用方法 |
IL298087A (en) | 2020-05-29 | 2023-01-01 | Sanofi Biotechnology | Compositions and methods for treating non-inflammatory pain in patients with rheumatoid arthritis |
AU2021305093A1 (en) * | 2020-07-08 | 2023-03-09 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-CTLA-4 antibodies |
BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
US20220160828A1 (en) | 2020-11-25 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
MX2023010794A (es) | 2021-03-26 | 2023-10-25 | Regeneron Pharma | Metodos y sistemas para el desarrollo de protocolos de mezcla. |
IL308864A (en) | 2021-06-01 | 2024-01-01 | Regeneron Pharma | In-house capillary electrophoresis tests and reagents |
CN117858722A (zh) * | 2021-08-18 | 2024-04-09 | 百奥泰生物制药股份有限公司 | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 |
US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
TW202328179A (zh) | 2021-09-20 | 2023-07-16 | 美商再生元醫藥公司 | 控制抗體異質性之方法 |
TW202331252A (zh) | 2021-10-07 | 2023-08-01 | 美商再生元醫藥公司 | Ph計校準與校正 |
US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
US20240198253A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1007208A (en) | 1911-07-21 | 1911-10-31 | Axel W Johnson | Window. |
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
CA1341152C (en) * | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
US5670373A (en) * | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
DE69029015T2 (de) | 1989-07-20 | 1998-01-22 | Tadamitsu Kishimoto | Antikörper gegen menschlichen Interleukin-6-Rezeptor |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5016784A (en) * | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
DK0610201T4 (da) | 1991-03-18 | 2008-02-04 | Centocor Inc | Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor |
AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
AU687763B2 (en) | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
ES2384222T3 (es) | 1994-10-07 | 2012-07-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo |
WO1996012503A1 (fr) * | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remede contre des maladies provoquees par la production d'il-6 |
ES2170815T5 (es) | 1994-12-29 | 2012-11-14 | Chugai Seiyaku Kabushiki Kaisha | Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino |
ATE330629T1 (de) | 1995-02-13 | 2006-07-15 | Chugai Pharmaceutical Co Ltd | Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
UA66757C2 (en) | 1996-02-26 | 2004-06-15 | Advanced Res & Tech Inst | Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration |
JP3471195B2 (ja) * | 1996-06-27 | 2003-11-25 | 中外製薬株式会社 | ナイトロジェンマスタード系抗癌剤と組合わせて使用するための骨髄腫治療剤 |
US5795695A (en) | 1996-09-30 | 1998-08-18 | Xerox Corporation | Recording and backing sheets containing linear and cross-linked polyester resins |
US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
PT1004315E (pt) | 1997-08-15 | 2008-07-09 | Chugai Pharmaceutical Co Ltd | Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
CN101239185A (zh) * | 1998-03-17 | 2008-08-13 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
DE69934698T2 (de) | 1998-08-24 | 2007-10-04 | Chugai Seiyaku K.K. | Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
WO2001027116A2 (en) | 1999-10-07 | 2001-04-19 | Eli Lilly And Company | Condensed dihydroquinolinone derivatives for inhibiting mrp1 |
US6629949B1 (en) * | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
EP1327681A4 (en) | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibodies |
EP1334731B1 (en) | 2000-10-25 | 2008-02-27 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
JP4889187B2 (ja) * | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
ES2624547T3 (es) * | 2001-11-14 | 2017-07-14 | Janssen Biotech, Inc. | Anticuerpos anti il 6, composiciones, métodos y usos |
US20050118163A1 (en) | 2002-02-14 | 2005-06-02 | Hidefumi Mizushima | Antibody-containing solution pharmaceuticals |
US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
EP1610820B2 (en) * | 2003-04-04 | 2013-08-21 | Genentech, Inc. | High concentration antibody and protein formulations |
SI1613350T1 (sl) | 2003-04-09 | 2009-08-31 | Genentech Inc | Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
EP1673396A1 (en) | 2003-09-22 | 2006-06-28 | BioVation GmbH & Co.KG. | Use of antibodies for reducing the biological effectiveness of il-6 |
DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
BRPI0506679A (pt) * | 2004-02-11 | 2007-05-15 | Warner Lambert Co | métodos de tratar osteoartrite com antagonistas de il-6 |
CN1989439B (zh) | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
RS20070027A (en) | 2004-07-26 | 2008-11-28 | Biogen Idec Ma Inc., | Anti-cd154 antibodies |
US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
WO2006046661A1 (ja) | 2004-10-28 | 2006-05-04 | Osaka University | インターロイキン-6阻害剤 |
EP1828250A2 (en) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
AU2006318583A1 (en) | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
EP2481753B1 (en) | 2005-12-13 | 2018-04-18 | Eli Lilly and Company | Anti-IL-17 Antibodies |
US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
CA2654794A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
CA2688275A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP4885308B2 (ja) * | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | 改良された抗体分子を含有する製剤 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
NZ603191A (en) | 2010-05-07 | 2015-02-27 | Xoma Technology Ltd | Methods for the treatment of il-1b related conditions |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
AU2014352801B2 (en) | 2013-11-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Compositions for the treatment of rheumatoid arthritis and methods of using same |
CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
AU2015317905A1 (en) | 2014-09-16 | 2017-03-16 | Regeneron Pharmaceuticals, Inc. | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
AU2016348418B8 (en) | 2015-11-03 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same |
CA3016880A1 (en) | 2016-03-07 | 2017-09-14 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
-
2010
- 2010-12-09 JO JOP/2010/0440A patent/JO3417B1/ar active
-
2011
- 2011-01-05 AR ARP110100021A patent/AR079836A1/es not_active Application Discontinuation
- 2011-01-07 DK DK11703294.6T patent/DK2521536T3/en active
- 2011-01-07 PT PT11703294T patent/PT2521536T/pt unknown
- 2011-01-07 CN CN201180012860.1A patent/CN102869346B/zh active Active
- 2011-01-07 US US12/986,223 patent/US9173880B2/en active Active
- 2011-01-07 TW TW100100565A patent/TWI533884B/zh active
- 2011-01-07 SI SI201131598T patent/SI2521536T1/sl unknown
- 2011-01-07 HR HRP20221139TT patent/HRP20221139T1/hr unknown
- 2011-01-07 PE PE2012000970A patent/PE20121687A1/es active IP Right Grant
- 2011-01-07 BR BR112012016618-2A patent/BR112012016618A2/pt not_active Application Discontinuation
- 2011-01-07 DK DK18174400.4T patent/DK3409269T3/da active
- 2011-01-07 RS RS20181286A patent/RS57903B1/sr unknown
- 2011-01-07 RU RU2012133970/15A patent/RU2554779C2/ru active
- 2011-01-07 PL PL11703294T patent/PL2521536T3/pl unknown
- 2011-01-07 TW TW104126027A patent/TWI587870B/zh active
- 2011-01-07 JP JP2012548134A patent/JP5805660B2/ja active Active
- 2011-01-07 ES ES20184418T patent/ES2925665T3/es active Active
- 2011-01-07 ES ES11703294.6T patent/ES2688070T3/es active Active
- 2011-01-07 RS RS20220856A patent/RS63567B1/sr unknown
- 2011-01-07 NZ NZ601114A patent/NZ601114A/en unknown
- 2011-01-07 PE PE2017000859A patent/PE20170948A1/es unknown
- 2011-01-07 EP EP20184418.0A patent/EP3756652B1/en active Active
- 2011-01-07 HU HUE18174400A patent/HUE051115T2/hu unknown
- 2011-01-07 RS RS20201334A patent/RS61045B1/sr unknown
- 2011-01-07 SI SI201131915T patent/SI3409269T1/sl unknown
- 2011-01-07 DK DK20184418.0T patent/DK3756652T3/da active
- 2011-01-07 MA MA35130A patent/MA33993B1/fr unknown
- 2011-01-07 SG SG2012047767A patent/SG182283A1/en unknown
- 2011-01-07 PL PL20184418.0T patent/PL3756652T3/pl unknown
- 2011-01-07 HU HUE11703294A patent/HUE040403T2/hu unknown
- 2011-01-07 UY UY0001033169A patent/UY33169A/es active IP Right Grant
- 2011-01-07 PT PT181744004T patent/PT3409269T/pt unknown
- 2011-01-07 MY MYPI2012002936A patent/MY156702A/en unknown
- 2011-01-07 HU HUE20184418A patent/HUE059811T2/hu unknown
- 2011-01-07 LT LTEP20184418.0T patent/LT3756652T/lt unknown
- 2011-01-07 ES ES18174400T patent/ES2818992T3/es active Active
- 2011-01-07 LT LTEP11703294.6T patent/LT2521536T/lt unknown
- 2011-01-07 SI SI201132064T patent/SI3756652T1/sl unknown
- 2011-01-07 LT LTEP18174400.4T patent/LT3409269T/lt unknown
- 2011-01-07 CA CA2790197A patent/CA2790197C/en active Active
- 2011-01-07 AU AU2011204311A patent/AU2011204311B2/en active Active
- 2011-01-07 EP EP22172959.3A patent/EP4098247A1/en active Pending
- 2011-01-07 WO PCT/US2011/020457 patent/WO2011085158A2/en active Application Filing
- 2011-01-07 KR KR1020127020667A patent/KR101787351B1/ko active IP Right Grant
- 2011-01-07 EP EP11703294.6A patent/EP2521536B9/en active Active
- 2011-01-07 MX MX2012007794A patent/MX2012007794A/es active IP Right Grant
- 2011-01-07 EP EP18174400.4A patent/EP3409269B1/en active Active
- 2011-01-07 PL PL18174400T patent/PL3409269T3/pl unknown
- 2011-01-07 PT PT201844180T patent/PT3756652T/pt unknown
- 2011-07-01 UA UAA201209619A patent/UA107211C2/ru unknown
-
2012
- 2012-07-05 ZA ZA2012/05035A patent/ZA201205035B/en unknown
- 2012-07-05 DO DO2012000193A patent/DOP2012000193A/es unknown
- 2012-07-06 CL CL2012001853A patent/CL2012001853A1/es unknown
- 2012-07-06 NI NI201200119A patent/NI201200119A/es unknown
- 2012-07-06 GT GT201200223A patent/GT201200223A/es unknown
- 2012-07-23 CR CR20120393A patent/CR20120393A/es unknown
- 2012-08-07 EC ECSP12012092 patent/ECSP12012092A/es unknown
- 2012-08-08 CO CO12132768A patent/CO6592078A2/es unknown
-
2015
- 2015-09-01 JP JP2015171642A patent/JP6053886B2/ja active Active
- 2015-09-22 US US14/861,565 patent/US10072086B2/en active Active
-
2018
- 2018-08-09 US US16/100,020 patent/US11098127B2/en active Active
- 2018-10-30 CY CY20181101111T patent/CY1121420T1/el unknown
- 2018-10-31 HR HRP20181821TT patent/HRP20181821T1/hr unknown
-
2020
- 2020-09-08 HR HRP20201428TT patent/HRP20201428T1/hr unknown
- 2020-11-11 CY CY20201101064T patent/CY1123909T1/el unknown
-
2021
- 2021-04-08 US US17/225,887 patent/US20210230283A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221139T1 (hr) | Stabilizirane formulacije koje sadrže antitijela protiv interleukin-6 receptora (il-6r) | |
IL283424B2 (en) | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) | |
SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
HRP20200007T1 (hr) | Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba | |
HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
RU2014140137A (ru) | Лекарственный препарат антитела к бета-амилоиду | |
HRP20120903T4 (hr) | Tekuća formulacija koja sadrži visoku koncentraciju protutijela | |
HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
HRP20161753T1 (hr) | Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom | |
NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
JP2015514090A5 (hr) | ||
NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
EA200970880A1 (ru) | Стабильные композиции на основе антител | |
FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
RU2015111341A (ru) | Композиции антитела и белка | |
HRP20240159T1 (hr) | Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste | |
NZ601125A (en) | Antibody formulation and therapeutic regimens | |
ES2860480T3 (es) | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos | |
RU2014142990A (ru) | Стабильные препараты связывающего средства на основе igg4 | |
HRP20161604T1 (hr) | Formulacija protutijela protiv il-17 | |
HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
HRP20220918T1 (hr) | Anti-transtiretinska antitijela |